Literature DB >> 7615353

High frequency of allelic imbalance at chromosome region 16q22-23 in human breast cancer: correlation with high PgR and low S phase.

S Skirnisdottir1, G Eiriksdottir, T Baldursson, R B Barkardottir, V Egilsson, S Ingvarrson.   

Abstract

The loss of genetic material from a specific chromosome region in tumors suggests that presence of tumor-suppressor genes. Loss of heterozygosity (LOH) or allelic imbalance (AI) on the long arm of chromosome 16 is a known event in sporadic breast cancer. To locate the commonly deleted regions, and therefore (a) candidate tumor-suppressor gene(s), a deletion map of chromosome 16 was made, using 10 microsatellite markers on 150 sporadic breast tumors. The 3 smallest regions of overlap (SRO) were detected on the long arm of chromosome 16. Allelic imbalance was observed with at least one marker in 67% of the tumors. One marker, D16S421, at the 16q22-23 region, showed the highest allelic imbalance, 58%. Tumors with and without AI on 16q were tested for correlation with clinico-pathological features of the tumors such as estrogen- and progesterone-receptor content (ER and PgR), age at diagnosis, tumor size, node status, histological type, S-phase fraction, AI on chromosome 3p, and ploidy. A correlation was found between AI on 16q and high PgR content, also low S-phase fraction (99% confidence limits). A comparison of tumors with and without AI at the D16S421 marker locus revealed a slight correlation with high PgR content. The survival data showed no difference between patients with AI on 16q and those with a normal allele pattern on the long arm of chromosome 16.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615353     DOI: 10.1002/ijc.2910640207

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Localization of a breast cancer tumour-suppressor gene to a 3-cM interval within chromosomal region 16q22.

Authors:  A Iida; R Isobe; M Yoshimoto; F Kasumi; Y Nakamura; M Emi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 2.  Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression.

Authors:  Kaumudi Bhawe; Deodutta Roy
Journal:  Cell Oncol (Dordr)       Date:  2018-07-25       Impact factor: 6.730

3.  Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1.

Authors:  E A Rakha; S E Pinder; C E Paish; I O Ellis
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

4.  Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer.

Authors:  C Huiping; J R Sigurgeirsdottir; J G Jonasson; G Eiriksdottir; J T Johannsdottir; V Egilsson; S Ingvarsson
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

5.  Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3.

Authors:  A M Cleton-Jansen; E W Moerland; J C Pronk; C G van Berkel; S Apostolou; J Crawford; A Savoia; A D Auerbach; C G Mathew; D F Callen; C J Cornelisse
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

6.  Preferential occurrence of breast carcinomas with loss of chromosome 16q and der (16) t (1;16) / der (1;16) in middle-aged patients with hyperplasia of mammary glands.

Authors:  H Tsuda; T Takarabe; T Fukutomi; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  2000-07

7.  Allelic loss of chromosome 16q in endometrial cancer: correlation with poor prognosis of patients and less differentiated histology.

Authors:  T Kihana; N Yano; S Murao; H Iketani; K Hamada; J Yano; S Murao; H Iketani; K Hamada; J Yano; S Matsuura
Journal:  Jpn J Cancer Res       Date:  1996-11

8.  E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.

Authors:  G Berx; A M Cleton-Jansen; F Nollet; W J de Leeuw; M van de Vijver; C Cornelisse; F van Roy
Journal:  EMBO J       Date:  1995-12-15       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.